H1N1 and Seasonal Flu Treatment
February 23, 2010 — JesseBelinda Ostrowsky, MD, assistant professor of medicine, division of infectious diseases, at Einstein and an infectious disease.
Go here to see the original:
H1N1 and Seasonal Flu Treatment
Belinda Ostrowsky, MD, assistant professor of medicine, division of infectious diseases, at Einstein and an infectious disease.
Go here to see the original:
H1N1 and Seasonal Flu Treatment
SINGAPORE : A lack of consistent maintenance on ventilation systems at hospitals and medical institutions could allow infectious diseases to thrive, experts have warned.
More here:
Experts air concern at ventilation (Bangkok Post – Thailand’s English news)
H1N1 is classified as category B infectious diseases so the hospital cannot mandate the isolation and treatment . Therefore the hospital cannot forcefully prevent the child to leave the hospital. 3. Before the patient left the hospital, …
Read more from the original source:
Dead body of child infected with H1N1 abandoned in a ditch | ChinaHush
CEL-SCI Corporation , a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.
The following are reader-submitted H1N1 questions with answers supplied by Dr. Alissa Ackelson, infectious diseases director of Infection Control, Genesis HealthCare System
See the article here:
Health official answers readers’ questions on H1N1 (Zanesville Times Recorder)
CEL-SCI Corporation , a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company’s first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine .
See the original post:
CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected … (PR Newswire via Yahoo!…
CEL-SCI Corporation , a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine has given clearance for the Company’s first clinical study to proceed.
Read this article:
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected … (PR Newswire via Yahoo! Finance)
Dr. Issa Ephtimios, a specialist in infectious diseases at the Center for Prevention and Treatment of Infection in Pensacola came to PJC on Tuesday to give a speech that was much needed at the college campus’ Student Center. His topic—H1N1, and…
Read this article:
H1N1 session raises questions (Santa Rosa Press Gazette)
Yale University is offering specialists in infectious diseases, emerging viruses, global health and epidemiology to speak on H1N1 . They can address many aspects of this outbreak, including the vaccine, diagnosis, treatment , …
Read the original:
MEDIA ADVISORY: President Declares H1N1 National Emergency; Yale …
WILMINGTON, DE–(Marketwire – 10/12/09) – iBio, Inc. (OTC.BB: IBPM – News ), a biotechnology company focused on developing vaccines and therapeutic proteins for the treatment of infectious diseases, is presenting today at the International Association for Biologicals New Cells for New Vaccines IV Conference in Wilmington, DE. Robert L. Erwin, iBio’s president, will present, Plant-Based Vaccine …